Evidence map›Paper›PMID 38625441›Full record

ReviewNeurogenetics2024

The Apo gene's genetic variants: hidden role in Asian vascular risk.

Valentinus Besin, Farizky Martriano Humardani, Trilis Yulianti, Sulistyo Emantoko Dwi Putra, Rina Triana, Matthew Justyn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurogenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Valentinus BesinFaculty of Medicine, Universitas Surabaya, Surabaya, Indonesia.
Farizky Martriano HumardaniFaculty of Medicine, Universitas Surabaya, Surabaya, Indonesia. farizky946@gmail.com.ORCID http://orcid.org/0000-0003-0487-6926
Trilis YuliantiProdia Education and Research Institute, Jakarta, Indonesia.
Sulistyo Emantoko Dwi PutraFaculty of Biotechnology, Universitas Surabaya, Surabaya, Indonesia.
Rina TrianaProdia Clinical Laboratories, Jakarta, Indonesia.
Matthew JustynFaculty of Pharmacy, Universitas Padjajaran, Jatinangor, Indonesia.
University of Surabaya · IDPadjadjaran University · IDUniversitas Sumatera Utara · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular risk factors, including diabetes, hypertension, hyperlipidemia, and obesity, pose significant health threats with implications extending to neuropsychiatric disorders such as stroke and Alzheimer's disease. The Asian population, in particular, appears to be disproportionately affected due to unique genetic predispositions, as well as epigenetic factors such as dietary patterns and lifestyle habits. Existing management strategies often fall short of addressing these specific needs, leading to greater challenges in prevention and treatment. This review highlights a significant gap in our understanding of the impact of genetic screening in the early detection and tailored treatment of vascular risk factors among the Asian population. Apolipoprotein, a key player in cholesterol metabolism, is primarily associated with dyslipidemia, yet emerging evidence suggests its involvement in conditions such as diabetes, hypertension, and obesity. While genetic variants of vascular risk are ethnic-dependent, current evidence indicates that epigenetics also exhibits ethnic specificity. Understanding the interplay between Apolipoprotein and genetics, particularly within diverse ethnic backgrounds, has the potential to refine risk stratification and enhance precision in management. For Caucasian carrying the APOA5 rs662799 C variant, pharmacological interventions are recommended, as dietary interventions may not be sufficient. In contrast, for Asian populations with the same genetic variant, dietary modifications are initially advised. Should dyslipidemia persist, the consideration of pharmaceutical agents such as statins is recommended.

Indexed as

Apolipoprotein A-VAsian PeopleGenetic Predisposition to DiseaseVascular DiseasesGenetic VariationHumansRisk FactorsApolipoprotein A-VApolipoproteinAsianEthnicGeneticVariantsVascular Risk Factor

Identifiers

PMID38625441
OpenAlexW4394847494

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.